冠昊生物收盘上涨2.84%，滚动市盈率161.80倍，总市值45.13亿元

Company Overview - Guanhao Biological Technology Co., Ltd. focuses on developing new products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure as core drivers of development [2] - The main products include biological dura (spinal) membrane patches, B-type dura (spinal) membrane patches, thoracic repair membranes, sterile biological wound dressings, Aireo breast patches, and Udeqing decellularized corneal implants [2] - The company is recognized as a "National Intellectual Property Advantage Enterprise" and has several subsidiaries that are classified as high-tech enterprises [2] Financial Performance - As of the first quarter of 2025, the company reported revenue of 94.79 million yuan, a year-on-year increase of 3.67%, and a net profit of 14.87 million yuan, also up 3.30%, with a gross profit margin of 77.05% [2] - The current stock price is 17.02 yuan, with a rolling price-to-earnings (PE) ratio of 161.80, marking a new low in 11 days, and a total market capitalization of 4.513 billion yuan [1] Industry Comparison - The average PE ratio in the medical device industry is 49.80, with a median of 36.84, positioning Guanhao Biological at 112th place within the industry [1][3] - The company’s static PE ratio is 164.60, while the industry average static PE is 47.81 [3]